Gilead Sciences Inc

NASDAQ: GILD
$91.69
+$1.47 (+1.6%)
Closing Price on November 6, 2024

GILD Articles

The August 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Here are 30 stocks with sustainable dividends for income investors to consider in their portfolios.
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Stocks saw profit-taking on Tuesday, but the major indexes were up on Wednesday ahead of the Federal Reserve’s expected interest rate cut in the afternoon. Earnings season is proving to be quite...
The top analyst upgrades, downgrades and initiations seen on Monday included Aflac, Apple, Chipotle Mexican Grill, Coca-Cola, Dell Technologies, Dish Network, Gilead Sciences, McDonald's and...
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Gilead and Galapagos each saw shares shoot up on Monday after the companies announced a new collaboration.
The top analyst upgrades, downgrades and initiations on Monday included Agilent Technologies, Amazon.com, American Water Works, Crocs, Deere, General Electric, Gilead Sciences, Slack and Teva...
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 28 short interest data has been compared with the previous report, and short interest in most...
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
The June 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data have been compared with the previous report, and short interest in most...
Goldman Sachs has muted any upside view by downgrading Gilead Sciences to Sell and lowering its price target.
The May 15 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks increased.